REGENXBIO Inc. (RGNX) is a publicly traded Healthcare sector company. As of October 12, 2026, RGNX trades at $8.05 with a market cap of $532.73M and a P/E ratio of -2.01. RGNX moved -0.29% today. Year to date, RGNX is -43.96%; over the trailing twelve months it is -33.69%. Its 52-week range spans $5.04 to $16.19. Analyst consensus is strong buy with an average price target of $22.00. Rallies surfaces RGNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Regenxbio to host investor event on sura-vec wet AMD program ahead of pivotal data readout: Regenxbio will host an investor event on Oct. 20, 2026, in New York, with a webcast option, to discuss its sura-vec wet AMD program ahead of pivotal topline data expected in the fourth quarter of 2026.
| Metric | Value |
|---|---|
| Price | $8.05 |
| Market Cap | $532.73M |
| P/E Ratio | -2.01 |
| EPS | $-3.79 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.19 |
| 52-Week Low | $5.04 |
| Volume | 1.02K |
| Avg Volume | 0 |
| Revenue (TTM) | $174.48M |
| Net Income | $-196.43M |
| Gross Margin | 0.00% |
10 analysts cover RGNX: 0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $22.00.